R
Rashmi Kumar
Researcher at University of North Carolina at Chapel Hill
Publications - 28
Citations - 3990
Rashmi Kumar is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: DNA damage & Lung cancer. The author has an hindex of 18, co-authored 26 publications receiving 3523 citations. Previous affiliations of Rashmi Kumar include Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Robert J. Motzer,Eric Jonasch,Neeraj Agarwal,Sam B. Bhayani,William P Bro,Sam S. Chang,Toni K. Choueiri,Brian A. Costello,Ithaar Derweesh,Mayer Fishman,Thomas H. Gallagher,John L. Gore,Steven L. Hancock,Michael R. Harrison,Won Kim,Christos Kyriakopoulos,Chad A. LaGrange,Elaine T. Lam,Clayton Lau,M. Dror Michaelson,Thomas Olencki,Phillip M. Pierorazio,Elizabeth R. Plimack,Bruce G. Redman,Brian Shuch,Brad Somer,Guru Sonpavde,Jeffrey A. Sosman,Mary A. Dwyer,Rashmi Kumar +29 more
TL;DR: The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma.
Journal ArticleDOI
Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Therese B. Bevers,Mark A. Helvie,Ermelinda Bonaccio,Kristine E. Calhoun,Mary B. Daly,William B. Farrar,Judy Garber,Richard Gray,Richard Gray,Caprice C. Greenberg,Rachel A. Greenup,Nora M. Hansen,Randall E. Harris,Alexandra S. Heerdt,Teresa Helsten,Linda Hodgkiss,Tamarya L. Hoyt,John G. Huff,Lisa K. Jacobs,Constance D. Lehman,Barbara Monsees,Bethany L. Niell,Catherine Parker,Mark D. Pearlman,Liane E. Philpotts,Laura B. Shepardson,Mary Lou Smith,Matthew Stein,Lusine Tumyan,Cheryl Williams,Mary Anne Bergman,Rashmi Kumar +31 more
TL;DR: This manuscript discusses the diagnostic evaluation of individuals with suspected breast cancer due to either abnormal imaging and/or physical findings.
Journal ArticleDOI
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Shaji Kumar,Natalie S. Callander,Melissa Alsina,Djordje Atanackovic,J. Sybil Biermann,Jason C. Chandler,Caitlin Costello,Matthew Faiman,Henry C. Fung,Cristina Gasparetto,Kelly N. Godby,Craig C. Hofmeister,Leona Holmberg,Sarah A. Holstein,Carol Ann Huff,Adetola A. Kassim,Michaela Liedtke,Thomas Martin,James L. Omel,Noopur Raje,Frederic J. Reu,Seema Singhal,George Somlo,Keith Stockerl-Goldstein,Steven P. Treon,Donna M. Weber,Joachim Yahalom,Dorothy A. Shead,Rashmi Kumar +28 more
TL;DR: The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myelomas, systemic light chain amyloidosis, and Waldenström's macroglobulinemia.
Journal ArticleDOI
Breast cancer version 3.2014
William J. Gradishar,Benjamin O. Anderson,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Lori J. Goldstein,Daniel F. Hayes,Clifford A. Hudis,Steven J. Isakoff,Britt-Marie Ljung,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Robert S. Miller,Mark D. Pegram,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Mary Lou Smith,Hatem Soliman,George Somlo,John H. Ward,Antonio C. Wolff,Richard Zellars,Dorothy A. Shead,Rashmi Kumar +30 more
TL;DR: The NCCN Guidelines specific to management of large clinical stage II and III tumors are discussed in this article and patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer.